We retrospectively analyzed NSCLC patients at National Cheng Kung University Hospital from January 2010 to December 2022, focusing on those who had disease progression beyond frontline EGFR‐TKI treatments. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.